Leading market players are investing heavily in research and development to expand their product lines, which will help the traumatic brain injuries treatment market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product establishments, mergers and acquisitions, higher investments, contractual agreements, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the traumatic brain injury treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the traumatic brain injury treatment industry to benefit clients and increase the market sector. In recent years, the traumatic brain injury treatment industry has offered some of the most significant advantages to medicine. Major players in the traumatic brain injuries treatment market, including Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., and others, are attempting to increase market demand by investing in research and development operations.
Integra LifeSciences Holdings Corp is a medical technology firm that develops and manufactures engineered collagen-based product lines. The firm's portfolio comprises advanced wound care, surgical instruments, specialty metal implants, orthobiologic products, dermal regeneration products, tissue-engineered injury dressings, and nerve and tendon repair products. Its neurosurgery products such as ultrasonic surgery systems, systems for measuring several brain parameters, cranial stabilization and brain retraction systems, and others.
Integra's products find application in neurosurgery, orthopedic extremity surgery, and reconstructive and general surgery. Integra serves outpatient surgery centers, hospitals, physicians, veterinarians and dental practices. The firm markets its solutions through direct market representatives and an extensive network of distributors ly. In September 2019, Integra Life Sciences completed the acquisition of Rebound Therapeutics, a manufacturer of disposable medical devices. With this acquisition, the company developed new products and a minimally invasive platform for neurosurgery.
Nihon Kohden Corp (Nihon Kohden) develops, manufactures and commercializes electronic medical equipment and other systems to support treatment in clinical areas of emergency response, testing, diagnosis, treatment, and rehabilitation. Its major products include patient monitors, electroencephalographs, evoked potential and electromyograph systems, electrocardiographs, defibrillators and hematology analyzers.
These products find applications in health management, home medical care, nursing and basic medical research. The company operates through branch offices and direct sales personnel in Japan and subsidiaries and distributors across the globe. Nihon Kohden is headquartered in Tokyo, Japan. In June 2019, Nihon Kohden launched a wireless Electroencephalogram (EEG) headset in the US called VitalEEG to promptly assess brain activity in unconscious patients.